Scarica l'app Stockscreener
2.32
0.00%
0.00
Dopo l'orario di chiusura:
2.32
Precedente Chiudi:
$2.32
Aprire:
$2.32
Volume 24 ore:
473
Relative Volume:
0.03
Capitalizzazione di mercato:
$29.12M
Reddito:
-
Utile/perdita netta:
$-3.15M
Rapporto P/E:
-7.6016
EPS:
-0.3052
Flusso di cassa netto:
$-2.23M
1 W Prestazione:
+5.45%
1M Prestazione:
-2.52%
6M Prestazione:
-1.28%
1 anno Prestazione:
+15.42%
Intervallo 1D:
$2.32
$2.32
Intervallo di 1 settimana:
$2.2095
$2.4482
Portata 52W:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Nome
Cytomed Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GDTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
2.32 | 25.39M | 0 | -3.15M | -2.23M | -0.3052 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cytomed Therapeutics Ltd Borsa (GDTC) Ultime notizie
CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia
CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India
CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare
CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 13.7% – Here’s What Happened - Defense World
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India - Yahoo Finance
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India - Yahoo Finance
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
CytoMed Therapeutics Limited Signs Business & Research Collaboration Agreement with Sunact Cancer Institute Private Limited to Advance Use of Allogeneic Off-The-Shelf Gamma Delta T Cells for Treatment of Solid Cancers in Proposed Phase 2 Clinical Tr - Marketscreener.com
CytoMed and SunAct partner for cancer immunotherapy trials - Investing.com
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in - Marketscreener.com
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - Simply Wall St
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Co-Chief Executive Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Director and Chief Operating Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics : Organisation and personnel changes Form 6 K - Marketscreener.com
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Yahoo Finance
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Emergence of Cell and Gene Therapy Community in Singapore - BSA bureau
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration | Value Investing NewsInvestor powered stock market news - Financial Content
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
Singapore-China collaboration to explore allogeneic gamma delta T cell technology for cancer treatment - BioSpectrum Asia
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
CytoMed Expands Research Collaboration into China After Entering Into MOU - StreetInsider
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - PR Newswire
CytoMed Therapeutics Granted Patent in China for Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Investing.com South Africa
Singapore's CytoMed Therapeutics announces collaboration with MD Anderson Cancer Center in US - BioSpectrum Asia
CytoMed and MD Anderson partner to use gdTc for cancer treatment - Pharmaceutical Technology
CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering - PR Newswire
Peter Choo-backed biomed firm CytoMed lists on Nasdaq - The Edge Singapore
GDTCCytoMed Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering - PR Newswire
IPO Update: CytoMed Therapeutics Aims For $11 Million U.S. IPO (Pending:GDTC) - Seeking Alpha
CytoMed Therapeutics (NASDAQ:GDTC) Stock Quotes, Forecast and News Summary - Benzinga
Malaysia-Singapore Collaborates In The Field Of Clinical Research - BusinessToday Malaysia
Compulsory vaccination: MOH prepared to hear views from all - thesun.my
Cytomed Therapeutics Ltd Azioni (GDTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):